Sanofi (NASDAQ:SNY) Issues Quarterly Earnings Results, Beats Expectations By $0.48 EPS

Key Points

• Sanofi beat quarterly expectations: The company reported $2.04 in EPS versus the $1.56 consensus estimate and revenue of $17.25 billion, up 16.2% year over year.
• Management raised its 2026 outlook to 13%–15% sales growth and 15%–17% business EPS growth, with Dupixent remaining the key growth driver and generating €5.7 billion in third-quarter sales.
• Sanofi continues to face pipeline and future-growth risks, including discontinued drug candidates, roughly €1.3 billion in expected 2027 divestment-related revenue reductions, pricing pressure, and Dupixent-related headwinds.

Sanofi (NASDAQ:SNY - Get Free Report) released its earnings results on Friday. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.56 by $0.48, Zacks reports. The business had revenue of $17.25 billion during the quarter, compared to analysts' expectations of $14.29 billion. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The firm's revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.91 earnings per share.

Here are the key takeaways from Sanofi's conference call:

• Q3 performance was strong: sales rose 14.3% to €14.4 billion, business operating income increased 19.7%, and business EPS grew 19.6%, supported by demand, favorable gross-to-net adjustments, product mix, and strict cost control.
• Sanofi upgraded its 2026 outlook to sales growth of 13%–15% and business EPS growth of 15%–17%. Management also expects business operating income and margin to increase annually through 2030, despite upcoming headwinds.
• Dupixent remained the central growth engine, generating €5.7 billion in Q3 with more than 1.5 million patients globally. Sanofi reaffirmed confidence in reaching at least €25 billion in annual sales by 2030 and expanded its Regeneron alliance with four next-generation immunology antibodies, including a potential long-acting follow-on product.
• Sanofi is concentrating resources on immunology, rare diseases, and vaccines while pursuing late-stage and commercial assets through disciplined BD and M&A. The company expects to provide more detail on its disease-area priorities, capital allocation, and Dupixent loss-of-exclusivity planning at a strategic update before year-end.
• R&D productivity remains a concern, with management acknowledging that Sanofi’s pipeline lags peers and discontinuing amlitelimab and itepekimab after benefit-risk reviews. The company also cautioned that 2027 sales will face roughly €1.3 billion of divestment-related reductions, a return to slightly negative pricing trends, and continued Dupixent profit-sharing and reimbursement headwinds.

Sanofi Stock Up 2.8%

Shares of NASDAQ:SNY traded up $1.21 during trading on Friday, reaching $44.34. 15,100,858 shares of the stock were exchanged, compared to its average volume of 3,453,743. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68. The stock has a fifty day moving average of $42.21 and a two-hundred day moving average of $44.35. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The firm has a market cap of $107.50 billion, a price-to-earnings ratio of 23.21, a price-to-earnings-growth ratio of 1.33 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on SNY. Morgan Stanley set a $49.00 price objective on shares of Sanofi in a research note on Wednesday, July 8th. Wolfe Research initiated coverage on shares of Sanofi in a research note on Friday, October 9th. They set a "peer perform" rating on the stock. Weiss Ratings upgraded shares of Sanofi from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, October 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Sanofi in a research note on Thursday, October 1st. Finally, Berenberg Bank reiterated a "buy" rating on shares of Sanofi in a report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $49.50.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company's portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.